Contrary to previous findings, low-dose aspirin therapy before conception and during early pregnancy may increase pregnancy chances and live births among women who have experienced one or two prior miscarriages, suggests a study by researchers at the National Institutes of Health.
National Institutes of Health
COVID-19 Patient Shed SARS-CoV-2 Up to 70 Days
Long-term SARS-CoV-2 shedding was observed from the upper respiratory tract of a female immunocompromised patient with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.
NIH RADx initiative advances six new COVID-19 testing technologies
The National Institutes of Health, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.
NIH expands clinical trials to test convalescent plasma against COVID-19
Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.
Probiotic skin therapy improves eczema in children, NIH study suggests
An experimental treatment for eczema that aims to modify the skin microbiome safely reduced disease severity and increased quality of life for children as young as 3 years of age, a National Institutes of Health study has found. These improvements persisted for up to eight months after treatment stopped, researchers report Sept. 9 in Science Translational Medicine.
NIH-funded project creates an encyclopedia detailing the inner workings of the human and mouse genomes
The Encyclopedia of DNA Elements (ENCODE) Project(link is external) is a worldwide effort to understand how the human genome functions.
NIH ACTIV vaccine working group weighs role of human challenge studies for SARS-CoV-2 vaccine development
Members of the National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for human challenge studies, to support SARS-CoV-2 vaccine development.